Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Streptococcus pneumoniae vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

NCT00334607
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
2-dose oral live attenuated G1P[8] human rotavirus vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 16 Weeks
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Benton, Arkansas • Cabot, Arkansas • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

NCT05425732
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, PCV20
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,663 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 6, 2026, 5:29 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
120
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033
View directory record Official record
Conditions
Healthy
Interventions
V118C, V118, PREVNAR 20™, Saline
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Hallandale, Florida • Hollywood, Florida • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

NCT01109108
View directory record Official record
Conditions
Nasopharyngeal Carriage of S. Pneumoniae
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 6, 2026, 5:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage

NCT00294021
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chinle, Fort Defiance, Whiteriver, AZ; Gallup, Shiprock, NM, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 6, 2026, 5:29 AM EDT
Recruiting Phase 4 Interventional

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

NCT06829238
View directory record Official record
Conditions
Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions
Metformin, Placebo, Jynneos, Capvaxvie
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Terminated Phase 4 Interventional

Antibody Production in Immune Disorders

NCT00023504
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 6, 2026, 5:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

NCT06181656
View directory record Official record
Conditions
Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia, Chemoradiation
Interventions
Pneumonia vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

NCT01967238
View directory record Official record
Conditions
Healthy
Interventions
IM Pneumococcal, meningococcal, or flu vaccine
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 5:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Effect of Obesity on Immune Response to Pneumovax 23

NCT02471014
View directory record Official record
Conditions
Obesity
Interventions
Pneumovax 23, Blood tests, Questionnaires
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 6, 2026, 5:29 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824181
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Hollywood, Florida • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

NCT05266456
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
835 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
13
States / cities
Hollywood, Florida • Sunrise, Florida • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

NCT01654263
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
55 Years to 74 Years
Enrollment
884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
7
States / cities
Decatur, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 6, 2026, 5:29 AM EDT
Not listed Phase 2 Interventional

Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department

NCT00380679
View directory record Official record
Conditions
High Risk for Serious Influenza, High Risk for Pneumonia
Interventions
Influenza vaccination, Pneumococcal polysaccharide vaccination
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2006 · Synced Oct 6, 2026, 5:29 AM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay

NCT00508950
View directory record Official record
Conditions
Healthy
Interventions
Large volume blood draw
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Early Phase 1 Interventional

Multi-peptide Vaccine With Basilixumab for Breast Cancer

NCT01660529
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
hTERT
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 6, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, Placebo, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 6, 2026, 5:29 AM EDT